Pardes Biosciences
YC S20 ↗San Francisco, US · Founded 2020 · Delaware corporation · 2 employees · Acquired · 3 known investors
Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.
Founders & leadership· Y Combinator alumni (S20)
UL
Uri LopatininFounder/CEO
UA
Uri A. LoptainExecutive Officer, Director
MA
Mark AueurbachDirector
MD
Michael D. VarneyDirector
JJ
J. Jay LobellDirector
HH
Heidi HensonExecutive Officer
EL
Elizabeth LacyExecutive Officer
LA
Lee ArnoldExecutive Officer
JB
James B. TananbaumDirector
Investors · 3
Reported raises · per SEC filings
Form D private placements▶$51.6MraisedFeb 2021 · 36 investors · BiotechnologyRule 506(b)
▶$51.6MraisedFeb 2021 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Uri A. LoptainExecutive Officer, Director
- Mark AueurbachDirector
- Michael D. VarneyDirector
- J. Jay LobellDirector
- Heidi HensonExecutive Officer
- Elizabeth LacyExecutive Officer
- Lee ArnoldExecutive Officer
- James B. TananbaumDirector
- Offering amount
- $51.6M
- Amount sold
- $51.6M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.